Search

Displaying results 4401 - 4410 of 6951 in total
  1. Drug

    Danegaptide

    go.drugbank.com/drugs/DB11821
    Investigational

    Danegaptide has been investigated for the treatment of Focus of Study is STEMI.

  2. Drug

    Acyline

    go.drugbank.com/drugs/DB11906
    Investigational

    Acyline has been investigated for the prevention and treatment of Hypogonadism and Contraception.

  3. Drug

    BMS-777607

    go.drugbank.com/drugs/DB12064
    Investigational

    BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.

  4. Drug

    Tipelukast

    go.drugbank.com/drugs/DB12435
    Investigational

    Tipelukast is under investigation for the treatment of IPF and Idiopathic pulmonary fibrosis.

  5. Drug

    Pf-04531083

    go.drugbank.com/drugs/DB12468
    Investigational

    Pf-04531083 has been investigated for the treatment of Pain and Chronic Pain.

  6. Drug

    Limonene, (+/-)-

    go.drugbank.com/drugs/DB19146
    Investigational

    Limonene, (+/-)- is under investigation in clinical trial NCT05525260 (Limonene for Pulmonary Nodule Chemoprevention).

  7. Drug

    Phenazepam

    go.drugbank.com/drugs/DB19164
    Investigational

    Phenazepam is under investigation in clinical trial NCT03017430 (Pregabalin for Opiate Withdrawal Syndrome).

  8. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas. … SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase II trials for cancer therapy.

  9. Drug

    Riltozinameran

    go.drugbank.com/drugs/DB17095
    ApprovedInvestigational

    It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419]

  10. Drug

    Rabeximod

    go.drugbank.com/drugs/DB05772
    Investigational

    Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.